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http://dx.doi.org/10.1016/j.ccr.2012.07.023SUMMARYPortal vein tumor thrombus (PVTT) is strongly correlated to a poor prognosis for patients with hepatocellular
carcinoma (HCC). In this study, we uncovered a causative link between hepatitis B virus (HBV) infection and
development of PVTT. Mechanistically, elevated TGF-b activity, associated with the persistent presence of
HBV in the liver tissue, suppresses the expression of microRNA-34a, leading to enhanced production of che-
mokine CCL22, which recruits regulatory T (Treg) cells to facilitate immune escape. These findings strongly
suggest that HBV infection and activity of the TGF-b-miR-34a-CCL22 axis serve as potent etiological factors
to predispose HCC patients for the development of PVTT, possibly through the creation of an immune-
subversive microenvironment to favor colonization of disseminated HCC cells in the portal venous system.INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the major health prob-
lems worldwide (Parkin et al., 2005). Since HCC is often diag-
nosed at an advanced stage, a large proportion of HCC patients
display symptoms of intrahepatic metastases or postsurgical
recurrence (Portolani et al., 2006), with a 5 year survival rate of
around only 30%–40%. In about a third of those instances,
metastatic tumors colonize the major branches of the portal
vein with the clinical symptom termed portal vein tumor
thrombus (PVTT) (Chambers et al., 2002), although the mecha-
nism underlying the formation of PVTT remains largely unknown.
Interestingly, almost all of the reported PVTT cases in the litera-
ture have been from developing countries, suggesting that thisSignificance
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patients in developed countries.
The development of HCC is believed to be associated with
hepatitis B virus (HBV) and hepatitis C virus (HCV) infection,
carcinogen/toxin exposure, and/or genetic factors. Among these
suspected etiological factors, HBV infection accounts for more
than 60% of the total liver cancer in developing countries and
less than a quarter of cases in developed countries (Jemal
et al., 2011). TheHBV-initiated tumorigenic process often follows
from or accompanies long-term symptoms of chronic hepatitis,
inflammation, and cirrhosis. The HBV infection-triggered inflam-
matory and/or fibrotic process, with extensive involvement of
cytokine/chemokine production/activation and leukocytes infil-
tration, is believed to create a microenvironment that favorssystem represents a critical barrier to prevent disseminated
uire specific activities to breach this barrier to successfully
so indicates that specific pathways are activated and utilized
rd, the findings presented here support the notion that HCC
immune-suppressive Treg cells via activation of the TGF-b
particular type of intrahepatic metastasis. Meanwhile, iden-
l therapeutic targets for the treatment of this deadly disease.
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Table 1. Clinical Characteristics of HCC patients with or
without PVTT
Clinical Characteristics
HCC without
PVTT (n = 54)
HCC with
PVTT (n = 234)
Age Mean ± SD 55.89 ± 10.25 48.08 ± 9.43
Gender Male/Female 43/11 211/23
Hepatitis virus HBsAg+ 41 209
HBsAg 12 2
HCVAb+ 0 3
HBsAg+ HCVAb+ 0 0
Unknown 1 20
Tumor number 1 46 214
R2 8 20
Median survival Days 964 263
AFP (ng/ml) <20 27 37
R20 27 197
Distant
metastasisa
Met/Total cases 3/54 66/234
Tumor number indicates number of primary tumor mass detected at the
time of surgical operation. AFP, a-fetal protein in the serum.
aDistant metastasis includes metastases to lung, bone, brain, abdominal
lymph nodes, adrenal gland, and abdominal wall.
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TGF-b-miR-34a-CCL22 Recruits Treg in HCC Metastasesthe development of HCC. Consistent with an important role for
HBV in HCC, persistent presence of HBV DNA in the serum of in-
fected individuals is found to be a strong indicator for the devel-
opment of HCC (Chen et al., 2006). Moreover, HCC patients with
high levels of serum HBV DNA have a poor prognosis, including
risks of death, metastasis, and recurrence following surgery
(Chen et al., 2009). However, it remains unclear whether the
HBV-initiated pathological process plays a specific role in late
stages of HCC progression such as formation of PVTT.
The cytokine transforming growth factor b (TGF-b) is known to
be a multifunctional factor that plays critical roles in various
aspects of liver pathogenesis, including chronic HBV/HCV infec-
tion (Marotta et al., 2004), cirrhosis (Matsuzaki, 2009), and
tumorigenesis (Massague´, 2008). Mounting evidence indicates
that one efficacious mechanism by which TGF-b promotes
tumor progression and metastasis is through repression of
immune surveillance within the tumor microenvironment (Bierie
and Moses, 2006; Massague´, 2008; Schmierer and Hill, 2007):
TGF-b can attract several types of innate and adaptive immune
cells to the tumor sites, enhance production of various cyto-
kines/chemokines, and alter the functional differentiation pro-
gram of those cells consequently promoting tumor growth,
invasion, and metastasis (Massague´, 2008).
Within the tumor microenvironment, FoxP3-expressing regu-
latory T (Treg) cells, which normally function as a dominant
inhibitory component in the immune system to actively maintain
self-tolerance and immune homeostasis through suppression of
various immune responses, have been demonstrated to be co-
opted by tumor cells to escape immune surveillance (Mailloux
and Young, 2010). Treg cells are frequently found to accumulate
within the tumor mass and ascites (Quezada et al., 2006). A
number of chemokines, including CCL22, which is also termed
macrophage-derived chemokine (MDC) and originally found to
be secreted by macrophages and dendritic cells upon stimula-
tion with microbial products, have been shown to recruit Treg
cells to modulate the immune response during the tumorigenic
process (Curiel et al., 2004). Although TGF-b has been found
to regulate the development of natural Treg cells in the thymus
during negative selection (Ouyang et al., 2010) and the extra-
thymical conversion of conventional T cells into suppressive
inducible Treg cells (Chen et al., 2003), it is unclear whether
TGF-b contributes to the accumulation of natural Treg cells
within the tumor microenvironment.
MicroRNAs (miRNAs) are small noncoding RNAs of 22
nucleotides that negatively regulate gene expression by blocking
protein translation and promoting degradation of the target mes-
senger RNA (Bartel, 2004). Changes in the expression profiles of
miRNAs have been linked to the development of various types of
human diseases, including cancer (Lujambio and Lowe, 2012).
MicroRNAs can act as oncogenic promoters or tumor suppres-
sors, depending on the functional nature of their specific target
genes within a specific cell or tissue type (Esquela-Kerscher
and Slack, 2006; Nicoloso et al., 2009). In the context of HCC,
recent reports indicate that alterations in the expression levels
of specific miRNAs are closely associated with specific stages
of the disease process, including intrahepatic metastasis (Ding
et al., 2010; Xiong et al., 2010). However, those studies did not
elucidate the specific roles of any those miRNAs in the progres-
sion of HCC to venous metastasis. In this study, we explored the292 Cancer Cell 22, 291–303, September 11, 2012 ª2012 Elsevier Inpossibility that specific miRNAs could act as mediators of
changes in the tumormicroenvironment during HCCprogression
and whether there was a potential link between HBV status as an
etiological factor and development of HCC-PVTT.
RESULTS
HBV Infection Status and TGF-b Signaling Activity Are
Positively Associated with PVTT Development in HCC
Patients
To investigate whether there is an etiological basis for the devel-
opment of PVTT, we analyzed the clinical data of 288 HCC
patients who received treatment in the Shanghai Eastern Hepa-
tobiliary Surgery Hospital and Guangzhou Sun Yat-sen Univer-
sity Cancer Center in China (Table 1). Among those patients,
234 developed PVTT with a poor prognosis in comparison to
the 54 patients who were negative for symptoms associated
with PVTT (Figure 1A). Within the PVTT positive group, the prog-
nosis of the patients showed a clear correlation with the types of
PVTT development (Shi et al., 2010) as measured by the pres-
ence of tumor lesions in different segments of the portal venous
system (Figure 1B).
In contrast to developed countries, HBV infection is the major
causative factor of HCC in China and other developing countries
with HBV positive (HBV+) status accounting for as much as 80%
of all HCC cases. In our patient cohort, 89% of the 234 HCC
patients with PVTT who were examined for their HBV status
were HBV+, but only 68% of 60 HCC patients without PVTT are
HBV+ (Figure 1C). This indicates that HBV infection status is
strongly associated with the development of PVTT, which was
not noted previously likely because PVTT has not been reported
as a major pathological feature of HCC patients in developed
countries. Consistent with a poorer prognosis of HCC patientsc.
Figure 1. HBV Infection Status and TGF-
b Signaling Activity Are Associated with
Development of PVTT in Human HCC
Patients
(A) Kaplan-Meier survival curves of HCC patients
with PVTT in comparison with those without PVTT
detected at the time of surgical operation. Clinical
characteristics of those patients are presented in
Table 1.
(B) Kaplan-Meier survival curves of HCC patients
shown in Table 1 with different degree of PVTT
development based on the extent of venous tumor
thrombus formation. Type I: Tumor thrombi
involving segmental branches of the portal vein or
above; Type II: Tumor thrombi involving right/left
portal vein; Type III: Tumor thrombi involving the
main portal vein trunk; Type IV: Tumor thrombi
involving the superior mesenteric vein.
(C) Percentage of HBV infection in HCC patients
with PVTT compared with those without PVTT.
‘‘Others’’ in the PVTT group include 3 HCV+
patients and 20 patients without the information
of their hepatitis viral infection status. ‘‘Others’’
in the HCC without PVTT group include one
HCC patient without information of hepatitis viral
infection status, as well as six additional patients
who were HBV that were not a part of the
original set of the 288 patients analyzed in (A)
and (B).
(D) Kaplan-Meier survival curves of HBV+ verses
HBV patients with HCC. The HBV+ group
includes 41 HCC patients without PVTT and 209
HCC patients with PVTT; The HBV group
includes 12 HCC patients without PVTT and 2
HCC patients with PVTT. Thirty of the 294 patients
displayed in (C) were excluded from this analysis
due to the lack of specific information: 6 HBV
patients without PVTT lacked survival information,
21 patients lacked hepatitis viral infection status,
and 3 HCV+ HCC patients.
(E) Rate of occurrence of pathological symptoms
associated with liver cirrhosis or fibrosis in the 234
HCC patients with PVTT shown in Table 1.
(F) IHC of phosphorylated Smad2 in HCC
samples. Left: Representative images showing
different intensities of nuclear staining of pSmad2.
Scale bars, 100mm. Lower panels represent
magnified pictures (53) of boxed area in the cor-
responding upper panels. Right: Box plot graph
showing the quantitative evaluation of pSmad2
staining intensity from a tissue microarray. Plot of
a box-plot (25%–75%) with whiskers to minimal
and maximal of all the score data was used. The
statistical differences between the three groups
were analyzed by one-way analysis of variance.
**p < 0.01.
(G) TGF-b expression levels in four different liver cell lines. Relative TGF-b1 mRNA level was measured by qRT-PCR and normalized to b-actin. **p < 0.01, n = 3.
(H) 105 HepG2 cells were transfected with 0.5 mg and 1 mg HBx or HBs expression construct, respectively. Twenty-four hr later, relative amounts of TGF-b1
secreted into the culture media were determined by ELISA. **p < 0.01 versus control vector group, n = 3. All error bars indicate mean ± SD.
See also Figure S1.
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nosis than HBV negative (HBV) patients (Figure 1D). Taken
together, the clinical data on our patients strongly support the
notion that HBV infection is a potent etiological factor predispos-
ing HCC patients to develop PVTT with a poor prognosis of the
disease.CanTo investigate possible mechanisms underlying the observed
link between positive HBV status and the development of PVTT,
we conducted further analysis on the pathological characteris-
tics of the 234 PVTT patients whose clinical history was recorded
in more detail. It has been well established that chronic HBV
infection is associated with induction of inflammation, fibrosis,cer Cell 22, 291–303, September 11, 2012 ª2012 Elsevier Inc. 293
Figure 2. Reduced Expression of miR-34a Is
Correlated with HBV-Positive HCC-PVTT
and Regulated by TGF-b
(A) Heat map of a partial list of miRNAs, which
expression levels differ among the indicated four
liver cell lines as determined using an RT-PCR-
based miRNA expression array.
(B) The relative level of miR-34a of indicated cell
lines was measured by qRT-PCR and normalized
to the level of U6. n = 3. **p < 0.01 calculated by
Student’s t test.
(C) The relative level of miR-34a in 26 PVTT tissue
samples (all HBV+), 30 primary tumor tissue
samples (17 HBV+ and 13 HBV), and 14 normal
liver tissues distal to tumor regions was deter-
mined by qRT-PCR and normalized to U6. **p <
0.01 calculated by Student’s t test.
(D) The relative level of miR-34a in different cell
lines mock-treated or treated with TGF-b1 for
indicated time points was measured by qRT-PCR
and normalized to U6. n = 3. **p < 0.01 calculated
by Student’s t test.
All error bars indicate mean ± SD. See also Table
S1 and Figure S2.
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patients were recorded to have liver cirrhosis or their tumors
were found to display pathological features of inflammation
and fibrosis at the time of surgery (Figure 1E). Since TGF-b is
among the most potent cytokines linked to liver inflammation,
fibrosis, and cirrhosis (Bissell, 2001), we next determined the
level of TGF-b signaling activity by measuring the status of
Smad2 phosphorylation in the nucleus using tissue microarrays
prepared from some of the 294 HCC patient samples. Strong
nuclear p-Smad2 staining, with a score of immunohistochem-
istry (IHC) intensity over 2 (++), was detected in 11 of 16 PVTT
tumor specimens and 22 of 66 HBV+ primary HCC tumor
samples. In contrast, seven of ten HBV HCC tumor samples
showed very low p-Smad2 levels with a score of IHC intensity
less than 1 (+) (Figure 1F). Consistent with the IHC results, the
levels of p-Smad2 determined by western blot from fresh tumor
tissues were also found to be significantly higher in HBV+ HCC
primary and PVTT tissue samples compared with those of
HBV tumors (Figure S1 available online). These data indicate
that high levels of TGF-b signaling activity are strongly associ-
ated with the development of HBV+ primary HCC and PVTT.
We alsomeasured the expression of TGF-b1, themain isoform
of the TGF-b family, in several liver cell lines, including WRL68
(nontumorigenic and HBV), HepG2 (HBV liver tumor cells),
HepG2.2.15 (HepG2-derivative with integration of the HBV
genome) (Delaney and Isom, 1998), and PVTT-1 (established
from a PVTT biopsy sample of a HBV+ HCC patient). As shown
in Figure 1G, TGF-b1 expression is much higher in HBV+ than
in HBV cell lines, providing support to the notion that TGF-b
may play a role in the progression of HBV-initiated HCC to
PVTT. To test whether HBV could have a more direct effect on
the expression of TGF-b, we transiently transfected HepG2 cells294 Cancer Cell 22, 291–303, September 11, 2012 ª2012 Elsevier Inc.with two HBV-encoded genes, HBx and
HBs, that have been reported to play
functional roles in HBV-associated carci-nogenesis (Lupberger and Hildt, 2007). Interestingly, transient
expression of these genes leads to increased TGF-b1 levels in
the cell supernatants within 24 hr in a dose-dependent manner
(Figure 1H). These results suggest that the presence of HBV en-
coded genes could have a direct influence on TGF-b expression
in liver cancer cells.
Expression of miR-34a Is Inversely Correlated with
Metastatic Potential in HBV+ HCC and Subject to
Negative Regulation by TGF-b
We then screened WRL68, HepG2, PVTT-1, and MHCC97 cell
lines using a quantitative RT-PCR (qRT-PCR)-based miRNA-
array strategy to identify miRNAs that may be functionally linked
to HCC metastases. MHCC97 is a HBV+ cell line that acquired
metastatic capacity through passages in nude mice (Tian et al.,
1999). As shown in Figure 2A and Table S1, the expression of
a group of miRNAs displays significant differences among these
four cell lines. ThemiR-34a, but not its family membersmiR-34b/
c, level is significantly lower in both HBV+ PVTT-1 and MHCC97
lines with high metastatic potential than in the other two cell
lines (Figure 2B). We selected miR34a for further investigation
because it is a well-established tumor suppressor (He et al.,
2007), and it was 1 of the 20-miRNA signature for prediction of
developing HCC venous metastasis and poor prognosis when
its expression is reduced in primary HCC tumors at the time of
diagnosis (Budhu et al., 2008).
We next determined whether this suppressed miR-34a ex-
pression represents a general pattern in HCC patients with
different HBV and PVTT status. We selected clinical samples
from the original 294 patients shown in Figure 1C based on the
initial evaluation of quality of RNA extracted from the tissue
specimen and analyzed the expression of miR-34a using qPCR
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tissue samples (17 HBV+ and 13 HBV), and 14 normal liver
tissues derived from areas distal to tumor lesions. As shown in
Figure 2C, the level of miR-34a was significantly lower in a large
fraction of the HBV+ primary and PVTT tumor samples than that
of the HBV primary tumor or normal liver tissues. Together
these data suggest that reduction in miR-34a expression is
frequently associated with HBV-initiated HCCduring the disease
progression toward the development of PVTT.
To determine whether TGF-b could have a direct role in
regulating miR-34a expression, we treated three HCC cell
lines with TGF-b and measured the levels of miR-34a at various
time points. TGF-b induced a rapid and robust reduction of
mature miR-34a in all of these cell lines, even though the basal
level of this miRNA in PVTT-1 cells was already very low (Fig-
ure 2D). Interestingly, the basal level of miR-34a in the HBV+
HepG2.2.15 cells was also reduced in comparison to their
parental HepG2 cells, indicating that presence of the HBV
genome could lead to suppression of miR-34a expression (Fig-
ure 2D), possibly through the autocrine action of TGF-b1
produced by the same cells (Figure 1G). To test this possibility,
we treated HepG2.2.15 cells with SB431542, an inhibitor of the
type I TGF-b receptor kinase and found an increase in the level
of miR-34a after blocking autocrine TGF-b signaling activity (Fig-
ure S2). Taken together with data shown in Figure 1, these results
indicate that reduction in miR-34a expression in HBV+ HCC
primary and PVTT tumor samples could be directly linked to
the high level of TGF-b signaling activity.
The Primary Target of miR-34a in PVTT Cells Is the
Chemokine Gene CCL22
We initially speculated that previously reported targeting CDK4,
CCNE2, and MET by the miR-34a/b/c family (He et al., 2007)
could be the potential mechanism underlying the association
between the reduced miR-34a expression and HCC-PVTT
development. However, we did not observe an inhibitory effect
on cell viability and proliferation, or any difference in cell migra-
tion when miR-34a mimic oligos were transfected into PVTT-1
cells (Figures S3A–S3C). Moreover, there were only slight nega-
tive effects observed on messenger RNA (mRNA) levels of these
three reported target genes with the presence of high-level miR-
34a in those cells (Figure S3D). Ectopic expression of miR-34a
also did not affect the growth of PVTT-1 tumors in vivo (Figures
S3E–S3G). These negative results strongly suggest that should
miR-34a have a tumor-suppressive effect on the development
of HCC-PVTT, it likely acts through a cell nonautonomous
mechanism.
One possible cell nonautonomous route for miR-34a to
execute its tumor-suppressive function is to impact the tumor
microenvironment by regulating the production of secreted
proteins. To test this hypothesis, we developed a qPCR-based
assay (Figure S3H) to investigate the potential effect of this
miRNA on the expression of cytokines, chemokines, and their
receptors in PVTT-1 cells and identified the chemokine CCL22
as the most significantly downregulated molecule upon miR-
34a overexpression (Figure 3A). In parallel, we employed estab-
lished bioinformatic procedures to predict putative miR-34a
target genes and identified CCL22 among the top hits associ-
ated with tumor metastasis. There are three putative miR-34aCantargeting sequences present in the 30 untranslated region
(UTR) of the human CCL22 (Figure 3B), two of which were also
found in the murine Ccl22 (data not shown). To determine if
miR-34a affect the expression of CCL22 through these putative
targeting elements, we employed a luciferase reporter carrying
these elements. A control construct was also generated in which
the three putative miR-34a targeting sequences were mutated.
As shown in Figure 3C, expression of the miR-34a mimic oligos
significantly suppressed the luciferase activity of the wild-type
reporter in a dose-dependent manner but had minimal effect
on the mutant reporter, supporting the notion that CCL22 is
a bona fide target of miR-34a.
To further validate CCL22 as a legitimate target ofmiR-34a, we
examined the expression of the endogenous CCL22 when
miR-34a expression was manipulated. As shown in Figure 3D,
ectopic expression of miR-34a significantly reduced CCL22
mRNA level. Interestingly, overexpression of miR-34b/c was
much less potent in reducing the expression of CCL22 (Fig-
ure S3I), even though they share the same seed targeting
sequence as miR-34a. Corresponding to a reduction in the level
of CCL22 mRNA, the secretion of CCL22 protein was also dras-
tically diminished with miR-34a ectopic expression (Figure 3E).
Reciprocally, introduction of antisense (AS)-miR-34a oligos into
the PVTT-1 cells was accompanied by an increase in CCL22
production in a dose-dependent manner (Figure 3F). To examine
this further, we also transfected the AS-miR-34a oligos into
HepG2 cells, which have a relatively higher basal level of miR-
34a compared to that of PVTT-1 cells (Figure 2B), and detected
an increase in the level of CCL22 mRNA (Figure S3J). Taken
together, these data suggest that the expression of miR-34a
and CCL22 is inversely correlated, most likely through the direct
targeting of the CCL22 gene by miR-34a.
An Inverse Relationship between the CCL22 Level and
the miR-34a Level Is Observed in HBV+ HCC Tumor
Samples
We next determined the expression pattern of CCL22 in four cell
lines with different HBV status. As shown in Figure 4A, higher
protein levels of CCL22 were detected in HBV+ (miR-34a low),
HepG2.2.15, and PVTT-1 cells than in HBV(miR-34a high),
WRL68, and HepG2 cells. We then measured mRNA levels of
CCL22 by qPCR using the same set of tissue samples shown
in Figure 2C and found that CCL22 mRNA level was significantly
increased in the group of HBV+ primary tumors and further
elevated in PVTT samples (Figure 4B). Importantly, the CCL22
mRNA level is inversely associated with the miR-34a level in
HBV+ primary tumor and PVTT tumors when the values for
each individual patient were plotted (Figure 4C). In contrast,
such association is not observed in HBV tumor samples or
normal liver tissues (Figure 4C). Again, these clinical data provide
strong support for our hypothesis that the elevation in CCL22 is
likely the result of reduced expression of miR-34a with a close
association with the positive status of HBV as the etiological
factor in the development of PVTT.
Reduced miR-34a Expression Is Correlated with
Enhanced Recruitment of Treg Cells
CCL22 has been implicated in the tumorigenic process by
binding to its receptor CCR4 on the surface of Treg cells,cer Cell 22, 291–303, September 11, 2012 ª2012 Elsevier Inc. 295
Figure 3. The Chemokine CCL22 Is a Bona
Fide Target of miR-34a
(A) PVTT-1 cells were transfected with 80 nM of
pre-miR-34a mimetic oligos, and a RT-PCR-
based expression array was carried out to deter-
mine the expression profile of 94 cytokines,
chemokines, and their receptors 6 hr later. The
expression pattern for 31 out of the 94 genes is
presented as representatives.
(B) Putative miR-34a binding sites in the 30 UTR of
human CCL22.
(C)HEK293Tcellswere transiently transfectedwith
pre-miR-34a mimetic or control oligos together
with the pGL3 control plasmid, a modified pGL3
plasmid containing thewild-type CCL22 30 UTR, or
a mutant CCL22 30 UTR with all three putative
target sequences mutated. Pre-miR-34a mimetic
or control oligos were added at the indicated
concentrations and the luciferase activity was
analyzed 24 hr later. Data are presented as relative
firefly luciferase units normalized with the value of
renilla luciferase. N = 3. **p < 0.01 (Student’s t test).
(D) PVTT-1 cells were transfected with 80 nM of
pre-miR-34amimetic oligos, and theCCL22mRNA
level was determined by qPCR 48 hr later and
normalized to GAPDH. **p < 0.01 (Student’s t test).
(E) PVTT-1 cells were treated as in (D), and CCL22
protein level in culture media was determined
by western blot. g-tubulin in corresponding cell
lysates was used as a loading control. n = 3.
(F) PVTT-1 cells were transfected with AS-miR-
34a or control oligos at the indicated concentra-
tions, and the CCL22 level in culture media was
determined by western blot 48 hr later. g-tubulin in
corresponding cell lysates was used as a loading
control. n = 3. All error bars indicate mean ± SD.
See also Figure S3.
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tumor microenvironment and promoting tumor cell escape
from immune surveillance. Thus, miR-34a may exert its cell
nonautonomous tumor-suppressive effect by regulating CCL22
expression and recruitment of Treg cells. To test this hypothesis,
we examined the ability of culture media from PVTT-1 cells
treated with different concentrations of AS-miR-34a oligos to
mobilize CD4+CD25+ cells freshly isolated from healthy donors,
the majority of which were FoxP3+ Treg cells (Figure S4A).
As shown in Figure 5A, inhibition of miR-34a correlates with
increase in the migratory activity of the Treg cells. Furthermore,
antihuman CCL22 neutralizing antibody significantly inhibited
the enhanced Treg cell migratory activity, indicating that miR-
34a inhibitor-induced Treg cell migration is dependent on the
production of CCL22.
To investigate the role of miR-34a in regulating Treg cell migra-
tion in vivo, we inoculated PVTT-1 cells with or without ectopic
expression of miR-34a into nude mice to form tumors and trans-
ferred freshly isolated CD4+CD25+ human Treg cells into those
mice via tail vein injection 14 days later. Together with determi-
nation of the expression status of CCL22 (Figure 5B), the
accumulation of human Treg cells inside the PVTT tumors
was assessed 48 hr later. As shown in Figures 5C and S4B,
miR-34a ectopic expression in PVTT-1 cells significantly
decreased accumulation of CD4+CD25+ Treg cells, but not
CD4+CD25 T cells inside the tumor.296 Cancer Cell 22, 291–303, September 11, 2012 ª2012 Elsevier InTo investigate whether there is a link between the expression
of miR34a and the level of Treg cells present in clinical samples,
we determined the expression profile of FoxP3, which is ex-
pressed primarily if not exclusively in Treg cells, in the same
set of tissue specimen used in experiments presented in Figures
2C and 4B. We observed higher levels of FoxP3 mRNA in HBV+
primary and PVTT tumor tissues (Figure 5D), indicating a greater
accumulation of Treg cells in HBV+ primary and PVTT tumor
tissues. Indeed, this postulation is supported by immunohisto-
chemical staining of a subset of the tumor specimens (Figure 5E).
Again, analyzed at the individual patient level, the increase of
FoxP3 mRNA inside the tumor mass is strongly associated
with the decrease of miR-34a level in HBV+ primary and PVTT
tumors (Figure 5F). Together these results provide strong
support to the notion that the suppression of miR-34a in HBV+
primary and PVTT tumor cells leads to elevated production of
CCL22 in the tumor microenvironment, which in turn augments
the recruitment of Treg cells and immune suppression.
TGF-b Induces CCL22 Production via Suppression
of miR-34a
We then tested whether TGF-b could affect CCL22 expression.
As shown in Figure 6A, CCL22 production by PVTT-1 cells
was increased following TGF-b treatment in a time-dependent
manner. To determine whether TGF-b exerts its effect via
the canonical signaling pathway, we added SB431542 to thec.
Figure 4. CCL22 Upregulation in PVTT Is Associated with Downregulation of miR-34a
(A) The CCL22 protein level in indicated liver cell lines was determined by western blot. g-tubulin was used as a loading control.
(B) Tissue specimens from the same set of patients as in Figure 2C were examined for the mRNA level of CCL22 by qRT-PCR and normalized to that of b-actin
(CCL22 mRNA was undetectable in four normal liver tissues and two HBV HCC primary tumor tissues). *p < 0.05, **p < 0.01 (Student’s t test). Mean ± SD.
(C) Clinical samples from the same set of specimen as in Figures 2C and 4Bwere analyzed in the four groups as indicated (CCL22mRNAwas undetectable in four
normal liver tissues and two HBV HCC primary tumor tissues). The correlation between miR-34a and CCL22 expression for each individual was assessed by
linear regression.
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completely blocked the ability of TGF-b to suppress miR-34a
or to induce CCL22 expression (Figure 6B). We also observed
that forced miR-34a elevation dose-dependently blocked the
ability of TGF-b to induce the expression of CCL22 in PVTT-1
cells (Figure 6C), suggesting that the effect of TGF-b on CCL22
expression was predominantly mediated by downregulation of
miR-34a. The functional relationship between miR-34a and
TGF-b observed here is similar to the previous reported inhibition
of TGF-b-induced epithelial-mesenchymal transition by ectopic
miR-34a expression (Siemens et al., 2011).
We next investigated the role of this TGF-b-miR-34a-CCL22
pathway on Treg cell migration. Culture media from PVTT-1 cells
treated with different concentrations of miR-34a mimic oligos
were tested for their capacity to mobilize freshly isolated human
CD4+CD25+ Treg cells. Consistent with the enhanced CCL22
production, Treg cell migratory activity was correspondingly
increased upon exposure to supernatant derived from PVTT-1
cells treated with TGF-b (Figure 6D). On the other hand, transfec-
tion of miR-34a mimic oligos into the PVTT-1 cells blocked the
effect of TGF-b-induced CCL22 expression and Treg cell migra-
tion in a dose-dependent manner (Figure 6D).
The Suppressive Function of miR-34a on Tumor Growth
and Metastasis Is Mediated by CCL22
The miR-34a-CCL22-Treg link demonstrated above provides us
with a plausible explanation for why miR-34a has little impact on
xenograft tumor formation by human PVTT-1 cells in athymicCannude mice (Figures S3F and S3G); the hosts have no T cells
(including Tregs) and exhibit little cellular immunity. The use of
murine model systems in which liver tumorigenesis can be
induced by gene manipulation or chemicals has very limited
application or relevance for our purpose since HBV is not an
etiological factor for the initiation of liver tumor formation in those
established models. Nevertheless, we have adopted a model by
employing a murine liver tumor cell line, Hepa1-6, originally
derived from the C57BL/6Jmouse strain that is immune-compe-
tent with fully functional T cell lineages. Consistent with what is
shown in Figures S3F and S3G, we found that miR-34a overex-
pression has minimal effect on Hepa1-6 tumor growth in nude
mice (Figure 7A), even though tumors derived fromHepa1-6 cells
express a low level of CCL22, which was reduced by the ectopic
expression of miR-34a (Figure 7B). In order to test the full poten-
tial of CCL22 to promote tumor metastasis in the context of an
immune-competent host, we engineered ectopic expression in
Hepa1-6 cells of the mouse CCL22 open reading frame (ORF)
without its 30 UTR so that it cannot be targeted by miR-34a.
Indeed, overexpression of CCL22 was not affected by the coex-
pression of miR-34a (Figure 7B). Subsequently, these four pop-
ulations of Hepa1-6 cells were inoculated subcutaneously into
C57BL/6J mice, and tumor growth was followed for 21 days.
As shown in Figure 7C, Hepa1-6 tumor growth was significantly
suppressed by miR-34a overexpression in immune-competent
mice in comparison to that of the vector control. In contrast,
CCL22 overproduction appeared to have a dramatic positive
effect on tumor growth. Importantly, miR-34a-induced tumorcer Cell 22, 291–303, September 11, 2012 ª2012 Elsevier Inc. 297
Figure 5. The miR-34a-CCL22 Pathway Regulates CD4+CD25+ Treg Cell Recruitment into the Tumor Microenvironment
(A) 1 3 105 human CD4+CD25+ Treg cells were tested by transwell assay for their migration toward culture media of PVTT-1 cells harvested 24 hr after the cells
were transfected with different amounts of AS-miR-34a or control oligos as indicated. CCL22 neutralizing or control antibody was added to the culture media of
AS-miR-34a oligos transfected PVTT-1 cells to determine the effect on Treg cell migration. Four hours after plating of the T cells in the upper chamber, migrated
Treg cells were quantified by Cell Counter analysis (n = 3, mean ± SD). **p < 0.01 (Student’s t test).
(B) CCL22 protein (left panel) or mRNA (right panel) level in xenograft tumors tissue samples derived from indicated PVTT-1 cells in nude mice was determined.
g-tubulin was used as a loading control for the western blot, and mRNA level of CCL22 was normalized to that of GAPDH. n = 4.
(C) Freshly isolated human CD4+CD25+ or CD4+CD25 T cells were injected via the tail vein into nude mice with xenograft tumors formed by PVTT-1 cells
ectopically expressing the vector control ormiR-34a as indicated, and tumors were extracted 48 hr later. Fluorescence-activated cell sorting was used to quantify
the number of T cells within 1 3 108 total cells from each tumor. n = 4, mean ± SD **p < 0.01 (Student’s t test).
(D) The mRNA level of FoxP3 in HBV+ HCC primary and PVTT samples from the same set of patients as in Figures 2C and 4B was measured by qRT-PCR and
normalized to that of b-actin (FoxP3 mRNA was undetectable in four normal liver tissues and two HBV HCC primary tumor tissues). *p < 0.05, **p < 0.01
(Student’s t test).
(E) Treg cell accumulation in HCC primary and PVTT samples was determined by immunohistochemistry staining using an anti-FoxP3 antibody. Representative
images from one set of the samples are shown. Arrows indicate FoxP3+ Treg cells stained in dark brown color. Scale bars, 100 mm. Lower panel represents
magnified views (53) indicated by boxes in the upper panel.
(F) Clinical samples from the same set of patients as in Figures 2C and 5D were analyzed in four groups as indicated (FoxP3 mRNA was undetectable in four
normal liver tissues and two HBV HCC primary tumor tissues). The correlation between miR-34a and FoxP3 expression for each individual was assessed by
linear regression. All error bars indicate mean ± SD.
See also Figure S4.
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the nontargetable CCL22 (Figure 7C), strongly suggesting that
the tumor-suppressive effect of miR-34a was mediated by
reducing the production of CCL22 as its predominant target.
To further investigate the mechanism by which miR-34a and298 Cancer Cell 22, 291–303, September 11, 2012 ª2012 Elsevier InCCL22 exert their effects on the growth of Hepa1-6 cells in their
syngeneic and immune-competent hosts, we quantified the
number of Treg cells infiltrated into the tumor mass formed by
the four types of cells. Consistent with the role of CCL22 as a
chemoattractant predominantly for Treg cells, the number ofc.
Figure 6. TGF-b Positively Regulates the
Production of CCL22 and Treg Cell Migra-
tion via Repression of miR-34a in PVTT-1
Cells
(A) Time course of TGF-b-induced CCL22 pro-
duction detected in the culture media of PVTT-1
cells. CCL22 was detected by western blot and
g-tubulin in corresponding cell lysate was used as
a loading control.
(B) PVTT-1 cells were pretreated with the control
solvent (DMSO) or SB431542 (SB) at 20 mM for
30 min and then treated with TGF-b1 for 12 hr. The
expression of miR-34a (left panel) and of CCL22
mRNA (right panel) were measured by qRT-PCR
and normalized to U6 or GAPDH, respectively (n =
3, mean ± SD). **p < 0.01 (Student’s t test).
(C) PVTT-1 cells were pretreated with various
doses of pre-miR-34a mimetic or control oligos
for 24 hr before TGF-b1 treatment for another 12 hr, as indicated. The level of CCL22 mRNA was measured by qRT-PCR and normalized to GAPDH (left panel).
CCL22 protein was detected by western blot and g-tubulin was used as a loading control (right panel).
(D) The same transwell assay as in Figure 5A was conducted with supernatants from PVTT-1 cells first transfected with pre-miR-34a or control oligos and 24 hr
later treated with TGF-b1 for another 24 hr. (n = 3, mean ± SD). **p < 0.01 (Student’s t test). All error bars indicate mean ± SD.
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TGF-b-miR-34a-CCL22 Recruits Treg in HCC MetastasesCD4+CD25+FoxP3+ cells detected in tumors correlated with the
level of CCL22 produced by each population of Hepa1-6 cells
(Figure 7D).
Using the same set of four populations of Hepa1-6 cells, we
assessed the effects of miR-34a and CCL22 on metastatic
potential following a well-established protocol (Bao et al.,
2004; Feng et al., 2011). The different batch of Hepa1-6 cells
carrying a luciferase reporter was inoculated intrasplenically
into C57BL/6J mice. After 21 days, luciferase signals derived
from abdominal metastatic growth were measured by the Xeno-
gen IVIS Lumina system (Caliper, Hopkinton, MA, USA). As
shown in Figures 7E–7G, ectopic miR-34a expression signifi-
cantly reduced metastatic growth. In contrast, CCL22 had
a potent effect in boosting the growth of Hepa1-6 cells inside
themouse liver and abdomen, completely overcoming any inhib-
itory effect by miR-34a (Figures 7E–7G).
To provide further support for the role of miR-34a in promoting
tumor metastasis using a different immune-competent mouse
model and to assess whether this miR-34a-CCL22-Treg path-
way can function in a different tumor context, we employed
a well-established mouse model of lung metastasis by 4T1
murine mammary tumor cells in their syngeneic hosts of the
BALB/c background (Morecki et al., 1998). We first determined
that miR-34a overexpression has the same negative effect on
CCL22 production in 4T1 cells as in human PVTT-1 cells (Fig-
ure S5A). We then inoculated 2 3 104 4T1 cells with or without
miR-34a overexpression into the mammary fat pad of female
BALB/c mice. Consistent with the results shown in Figure 7C,
the size of tumors from 4T1 cells ectopically expressing miR-
34a was smaller than that of control cells after 21 days of growth
(Figure S5B). To test if Treg cells were differentially recruited to
the 4T1 tumors upon manipulation of tumor miR-34a levels, we
quantified the number of CD4+CD25+FoxP3+ Treg cells inside
the tumor mass of the collected primary tumor tissue. A signifi-
cant reduction in the number of Treg cells was observed from
tumors derived from 4T1 cells with ectopic miR-34a expression
(Figure S5B). To gain further insight using this system, we
repeated these experiments by implanting 5 3 104 4T1 cells.CanSeven or fourteen days postimplantation, mice were subjected
to imaging analysis to quantify the metastatic tumor mass in
the lung. As shown in Figure S5C, ectopic miR-34a expression
completely blocked the formation of lung metastases by the
4T1 cells, likely through the reduction of CCL22. Taken together,
our results from both liver and mammary tumor models demon-
strate the potent antimetastatic effect of miR-34a, which is
mediated primarily by suppressing Treg cell recruitment via
inhibition of CCL22 production.
DISCUSSION
The presence of PVTT in patients with HCC is one of the most
significant factors for a poor prognosis in developing countries
(Lin et al., 2011; Shi et al., 2010). Once PVTT is formed, the tumor
cells may spread along the portal vein, leading to extensive bilo-
bar intrahepatic metastasis. Portal vein obstruction also causes
further deterioration in liver function often resulting in liver failure.
In addition, PVTT-induced portal hypertension can cause intrac-
table ascites and esophageal variceal bleeding. The symptoms
associated with PVTT present a major challenge for the treat-
ment of HCC in such patients. Despite its clinical importance,
however, the mechanism associated with the pathogenesis of
PVTT remains largely unclear.
In the current study, we extensively investigated the risk
factors and mechanism underlying the development of this
important intrahepatic metastasis. Consistent with a previous
report (Takizawa et al., 2007), PVTT also strongly correlates
with poor prognosis in our cohort of HCC patients. Importantly,
we uncovered a link between the development of PVTT and
positive HBV infection status, as well as a high level of TGF-b
signaling activity. Compared with a rate of 14.3% of PVTT
metastasis in HBV HCC patients, a much higher rate of
82.5% of PVTT development was found among HBV+ patients.
Thus, our findings strongly suggest that HCC initiated by HBV
infection predisposes those patients for development of PVTT,
which in turn accounts for the high mortality rate for HCC
patients in the developing countries, such as China (Jemalcer Cell 22, 291–303, September 11, 2012 ª2012 Elsevier Inc. 299
Figure 7. Impact of miR-34a and CCL22 on Tumor Growth and Metastasis Associated with Treg Cell Recruitment to the Tumor Microenvi-
ronment
(A) 5 3 105 pTRIPZ-miR-34a or pTRIPZ-mock stably transfected Hepa1-6 cells were subcutaneously injected into 6-week-old nude mice. Three weeks later,
tumors derived from indicated cells were isolated and shown in the left panel with the plot of their weight displayed in the right panel. n = 4.
(B) pTRIPZ-miR-34a or pTRIPZ-mock together with pcDNA3-CCL22-ORF or pcDNA3 vector as indicated were stably transfected into Hepa1-6 cells to generate
population of cells. 23 106 of each population of those cells were subcutaneously injected into 6-week-old male C57BL/6J mice. The animals were administered
Doxcycline 2 mg/mouse by gavage every 2 days. After 21 days, CCL22 in tumor tissueswas detected bywestern blot, and g-tubulin was used as a loading control.
(C) The tumor growth curves (left panel) for the same four populations of stably transfected Hepa1-6 cells as described in (B) were measured, and the tumors
isolated 21 days after inoculation are shown in the right panel. **p < 0.01 (Student’s t test). n = 4 per experimental group; experiment repeated three times.
(D) Treg cells were quantified in tumors grown from the four populations of Hepa1-6 cells in C57BL/6J mice. The number of Treg cells from 50 mg of tumor tissue
derived from indicated cells was determined via cell counting by flow cytometry.
(E) The same four Hepa1-6 populations as described in (B) coexpressing a luciferase reporter were introduced into the C57BL/6J mice via intrasplenic injection.
After 21 days, luciferase signals derived from abdominal metastatic tumor growth, as shown in the representative images, were determined by the Xenogen IVIS
Lumina system.
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TGF-b-miR-34a-CCL22 Recruits Treg in HCC Metastaseset al., 2011), where a large population has been exposed to HBV
infection and become chronic carriers of the virus (Han, 2009).
Consequently, HCC should be stratified to at least two major
categories based on the pathological nature of the likely initiating
step of tumorigenesis associated with the dominant etiological
factor: HBV (possibly HCV as well) infection versus other causes
such as toxin exposure or alcoholism-induced cirrhosis. One
protein encoded by the HBV genome, HBx, has been well estab-
lished to play a critical role in HBV-associated liver pathogen-
esis, including tumorigenesis by functioning as an oncogene
(Benhenda et al., 2009; Kew, 2011). Together with inactivation
of p53 and activation of the Wnt pathway commonly detected
in HCC (Ding et al., 2005; Feitelson and Duan, 1997), HBx and
possibly other HBV-encoded proteins could act as the drivers
for HCC initiation and progression. In themeantime, pathological
changes associated with the HBV-initiated tumorigenic process,
both cell autonomous and nonautonomous, that predispose
patients to the development of PVTT could be distinct from
those genetic and epigenetic alterations in hepatocytes and their
microenvironment induced by etiological factors other than HBV
(Herceg and Paliwal, 2011). In this regard, treatment options
should be developed that tailor to the specific molecular nature
of HCC pathogenesis associated with HBV to improve the prog-
nosis of those patients.
The full spectrum of pathological factors that contribute to
the development of PVTT of HBV+ HCC patients remain to be
adequately elucidated, mainly because the lack of a suitable
mouse model system that could faithfully and more completely
mimic the pathological process of tumor thrombosis formation
in human HCC patients since HBV is incapable of infecting
mouse hepatocytes. Nevertheless, our discovery of the TGF-
b-miR-34a-CCL22 pathway, which could render the microenvi-
ronment of liver tissue around the portal venous system immuno-
suppressive to favor the colonization and expansion of HCC
cells disseminated from the primary tumor site, represents
a major step toward addressing this critical question. Following
HBV infection and during subsequent pathological processes,
such as inflammation and/or fibrosis, a change in the liver micro-
environment may begin with a significant increase in the activity
of TGF-b signaling, which in turn suppresses the expression
of miR-34a, resulting in the enhanced production of the chemo-
kine CCL22 and recruitment of Treg cells. The potent immune-
suppressive activity of Treg cells causes subversion of immune
responses against tumor cells escaped from the primary tumor,
leading to the development of intrahepatic venousmetastasis. In
this regard, CCL22, a secreted molecule capable of acting on
both tumor and immune cells, could be considered as a potential
therapeutic target for the development of an effective treatment
for this disease.
The paradoxical results from the different phenotypes of miR-
34a overexpressing tumor cells in immune-compromised nude
mice and in immune-competent C57BL/6J and BALB/c mice(F) Luciferase signal levels from the four groups of mice shown in (E) was normaliz
relative metastatic growth by each of the indicated Hepa1-6 cell populations. *p
repeated three times.
(G) Representative images showing the formation of tumor metastases in the
metastatic tumors in the mouse liver.
All error bars indicate mean ± SD. See also Figure S5.
Canprovided the key evidence that this miR-34a-CCL22 pathway
plays a central role in modulating the tumor immune microenvi-
ronment. A wealth of evidence suggests that Treg cells, espe-
cially CD4+CD25+ Treg cells, act to sustain self-tolerance and
immune homeostasis by suppressing a wide variety of physio-
logical and pathological immune responses against self and
nonself, as well as quasi self-tumor antigens (Sakaguchi, 2004;
Shevach, 2002). However, how these naturally arising Treg
cells are recruited into the tumor microenvironment to nega-
tively control immune tumor surveillance has remained largely
unknown. Several studies indicated that TGF-b could induce
naive T cell differentiation into Treg cells (Liu et al., 2008), consis-
tent with the close association in expression profiles of TGF-b
and Treg cell marker FoxP3 in multiple types of human tumors.
However, this function for TGF-b signaling in regulating the
development of natural Treg cells cannot adequately explain
the observed recruitment of Treg cells into tumor microenviron-
ment, which is particularly important for tumor progression and
metastasis. In this regard, our findings provide the critical exper-
imental evidence on the important roles of TGF-b and cytokines/
chemokines induced by TGF-b in the creation of a favorable
microenvironment for tumor metastasis through regulation of
Treg cell recruitment.EXPERIMENTAL PROCEDURES
Patients and Tissue Samples
Clinical samples were obtained from 294 HCC patients treated at the Shanghai
Eastern Hepatobiliary Surgery Hospital and Guangzhou Sun Yat-sen Univer-
sity Cancer Center in China. Among those patients, 234 were diagnosed
with developed PVTT and 60 were negative for symptoms associated with
PVTT. Within the PVTT positive group, the types of PVTT development as
measured by the presence of tumor lesions in different segments of the portal
venous system (Shi et al., 2010). All of the samples and associated clinical
information were collected with informed consent of patients and all of the
experiments were approved by the Internal Review and Ethics Boards of the
Shanghai Eastern Hepatobiliary Surgery Hospital and Guangzhou Sun Yat-
sen University Cancer Center, respectively.
Cell Culture
HepG2, Hepa1-6, and WRL68 cells were obtained from the American Type
Culture Collection and cultured under standard conditions. PVTT-1 cells
have been described previously (Wang et al., 2010). MHCC97 cells were ob-
tained from Dr. Z. Tang. 4T1 cells were obtained from Dr. R.A. Weinberg.
CD4+CD25+ T cells and CD4+CD25 T cells were separately purified with
Dynabeads Regulatory CD4+CD25+ T cell kits (Invitrogen, Grand Island, NY,
USA) from human blood (Gulf Coast Regional Blood Center, Houston, USA).
Reagents and Plasmids
AS-miR-34a and scramble control locked nucleic acid oligonucleotides were
purchased from Exiqon (Vedbaek, Denmark). Pre-miR-34a mimic processor
and scramble control oligonucleotides were purchased from Ambion (Grand
Island, NY, USA). The miR-34a and miR-34b/c expression vectors were con-
structed using TRIPZ lentiviral system from Thermo Scientific Open Bio-
systems (Lafayette, CO, USA).ed to that of control mice without tumor growth and computed as the values for
< 0.05, **p < 0.01 (Student’s t test). n = 4 per experimental group; experiment
mouse liver by each of the indicated Hepa1-6 populations. Arrows indicate
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Total RNA, inclusive of the small RNA fraction, was extracted from cultured
cells with a mirVana miRNA Isolation Kit (Ambion). RT-PCR-based array for
detection of mature miRs and U6 was achieved with gene-specific primers.
Animal Studies
All research involving animals complied with protocols approved by the Duke
University Animal Care and Use Committee. The in vivo migration assays were
measured following an established method (Curiel et al., 2004). For sponta-
neous metastasis assays, the metastatic formation was monitored by the
appearance of luciferase activities by imaging apparatus of IVIS systems
(Caliper).
MTT and BrdU Assays
In vitro cell viability was measured by MTT assay following established proto-
cols (Feng et al., 2011). A bromodeoxyuridine (BrdU) incorporation assay was
conducted according to the manufacturer’s instruction (BD PharMingen, San
Diego, CA, USA).
Immunoblots
Cell lysates and supernatants were resolved by electrophoresis, transferred
to a polyvinylidene floride membrane, and probed with antibodies against
g-tubulin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or CCL22 (R&D
Systems, Minneapolis).
Immunohistochemistry
Detection of phospho-Smad2 (Cell Signaling Technology, Danvers, MA, USA)
and FoxP3 (Abcam, Cambridge, MA, USA) was performed on 5 mm paraffin
sections of tissue samples with the indicated antibodies, using Vectastain Elite
ABC kits (Vector, Burlingame, CA, USA) and ImmPACT DAB Substrate
(Vector). For pSmad2, the score was evaluated as four levels from 0 (),
1(+), to 2(++), 3(+++).
Fluorescence-Activated Cell Sorting
Cells were stained with monoclonal antibodies and analyzed on a FACSCanto
(Becton Dickinson, Franklin Lakes, NJ, USA). Antibodies were mouse anti-
human CD4-APC (Biolegend, San Diego, CA, USA), mouse antihuman
CD25-PE (Biolegend), mouse antihuman FoxP3-PB (Biolegend), PB anti-
mouse CD4 (eBioscience, San Diego, CA, USA), PE antimouse CD25
(eBioscience), and PE-Cy5 antimouse/rat Foxp3 (eBioscience).
Migration Assay
Cell migration was assessed as described (Curiel et al., 2004) using
CD4+CD25+ Treg cells. PVTT-1 tumor cell supernatants were added to the
lower chamber. Antibody against CCL22 and control IgG were obtained
from R&D Systems.
Statistical Analyses
Data are presented as mean ± SD. Student’s t test was used for comparisons.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://
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